DOC. LW-WEB-01 · REV B · ISSUED 2026
PUBLIC / NON-CONFIDENTIAL
LAWSONE
Formulation, de-risked

Development-ready generic dossiers, with every fact carrying provenance

Lawsone is a dossier production platform: an in-house agent pipeline turns public regulatory records into complete, licensable formulation dossiers for marketed drugs - master formula, manufacturing procedure, specifications, and equivalence evidence, validated by simulation. You license the dossier; you skip the guesswork.

One line gets you the non-confidential dossier index. Replies come from the dossier's author, usually within 48 h. Write to aws@lawsone.si.

7
licensable dossiers, built one at a time
40+
provenance-tagged data points per dossier
f2 ≥ 50
f2 similarity, all compendial media (simulated)
5–8 wk
to a Trial-1 batch; in-house paths run quarters

Section 1 · Current assets / details under NDA

ASSET LW-ACLASS: ORAL SOLIDSTATUS: LICENSABLE
Dossier A / solid oral, conventional process

20 mg immediate-release tablet. Candidate master formula plus granulation process and specifications on standard equipment; no special infrastructure required. Simulation-supported equivalence; documented failure-mode analysis included.

Compound identity under NDA
ASSET LW-BCLASS: NANOSUSPENSIONSTATUS: LICENSABLE
Dossier B / nanocrystal platform

145 mg nanocrystal tablet requiring wet bead-milling. Full quantitative recipe confirmed across three regulatory regions; mill parameters, stabilizer system, and discriminating dissolution design included.

Compound identity under NDA
Asset registry · full pipelineCompound identities under NDA
AssetClassStatus
LW-AImmediate-release oral solid, conventional processLicensable
LW-BNanocrystal tablet, wet bead-milling platformLicensable
LW-CAmorphous solid dispersion, tabletLicensable
LW-DAmorphous solid dispersion, softgel and tabletLicensable
LW-ELipid-based softgelLicensable
LW-FHard capsule plus intravenous formLicensable
LW-GPermeation-enhanced oral tablet, peptideLicensable

Section 2 · The provenance standard

Verified
Established, basis included in-file
Inferred
Reasoned estimate, basis shown
Hypothesized
Flagged for experimental test

Every figure in a Lawsone dossier carries a confidence tag. You always know what is established and what is inference, so your regulatory and legal teams can diligence the file line by line instead of trusting a black box.

We never claim the innovator's confidential manufacturing record. What we deliver is a defensible point inside the equivalence region: a candidate formula and process whose every number is graded — verified, inferred, or flagged to test in your first batch.

Excerpt · Dossier LW-A · Claims tableValues redacted · full file under NDA
ClaimTagValue
Reference-product dissolution profile, all compendial mediaVerified
Excipient grades and supplier classVerified
Target binder and disintegrant levels, % w/wInferred
Critical process parameter windowsHypothesized
Optimal Trial-1 batch size for pilot-BEHypothesized

Section 3 · What a license includes

  • Master formula: per-unit and per-batch, with excipient grades and suppliers
  • Manufacturing procedure: CPPs, in-process controls, scale-up notes
  • Specifications: API and excipient specs, each provenance-tagged
  • Equivalence evidence: dissolution rationale plus simulation package
  • Robustness screen: Monte-Carlo sensitivity on critical parameters
  • Pilot-BE appendix: study design for a fasted pilot bioequivalence trial

Section 4 · Engagement

01
Teaser

Non-confidential overview: asset class, dossier depth, licensing terms.

02
NDA

Mutual NDA, then compound identity plus the stage-1 data pack.

03
Diligence

Your team reviews the dossier line by line: provenance map, dissolution overlays, robustness report.

04
Term sheet

Territorial license: upfront, milestones, profit share. Formula under signature.

Section 5 · Commission a dossier / any molecule

The licensed assets above are what is ready today. The desk also builds dossiers to order: name the molecule, dosage form, and target markets, and we scope feasibility, timeline, and price before you commit to anything.

Best fits: oral solids on conventional equipment, nanocrystal and amorphous-dispersion products, lipid and softgel fills, and reference products with hard-to-read formulations. Send the request; a feasibility answer comes back within a few days.

FORM. LW-REQ-01DOSSIER COMMISSION REQUESTPUBLIC / NON-CONFIDENTIAL
Opens your mail app addressed to aws@lawsone.si. Nothing confidential travels through this page.

Section 6 · The company

RECORD. LW-CO-01COMPANY REGISTRYPUBLIC
Entity
Lawsone
Founded
September 2026
Base
Amman, Jordan (GMT+3)
Founder
Aws Ahmad, dossier author
Focus
Deformulation and generic dossier development
Lawsone is an independent pharmaceutical R&D company. The desk reconstructs candidate formulations and manufacturing procedures for marketed drugs from public regulatory records and laboratory evidence, then validates equivalence in silico - dissolution similarity and virtual bioequivalence - before a licensee runs its first batch. Research, simulation, and quality control run on an agent stack the company develops in-house.